eAG: translating A1c into everyday glucose
Estimated Average Glucose is a calculation that translates your long-term blood sugar pattern into a single everyday number. It is derived from hemoglobin A1c, the fraction of hemoglobin in red blood cells that becomes coated with sugar. Glucose circulating in your blood drifts into red blood cells and sticks to hemoglobin over time (non-enzymatic glycation). Because red blood cells live for about three months, the degree of coating mirrors the typical glucose environment. EAG takes that A1c signal and expresses it as an average glucose level.
What does it reflect? EAG summarizes the glucose exposure your tissues experience around the clock over recent months, smoothing out meal spikes and day‑to‑day swings. It serves as a practical bridge between a lab marker and how glucose behaves in daily life, complementing spot checks or sensor readings. In plain terms, it tells you the usual glucose "climate" your body has been living in (chronic glycemic exposure), which is the context cells and organs respond to over time.
Why average glucose matters across organs
Estimated Average Glucose translates hemoglobin A1c into the language of everyday glucose, summarizing your typical blood sugar over the past 2–3 months. Because it reflects how often tissues bathe in glucose, it speaks to whole‑body stress on blood vessels, the heart, kidneys, eyes, nerves, and the brain—not just the pancreas.
Big picture: eAG connects daily readings to long‑term tissue exposure and risk. It correlates with complications in the eyes, kidneys, nerves, and the cardiovascular system, and complements time‑in‑range metrics. Conditions that alter red blood cell lifespan (anemia, kidney disease, hemoglobin variants, pregnancy) can make eAG less reflective of true glucose patterns.
What different eAG numbers signal
In general, people without diabetes land around the low 100s, with within reference ranges values toward the lower end so long as symptoms of low sugar are absent. Numbers rising into the high 110s to mid‑130s signal prediabetes, and about 140 or higher aligns with diabetes.
When eAG is unusually low, it means average glucose has been kept down by insulin (endogenous or injected) outpacing liver glucose release. The brain, which relies on steady glucose, may protest with shakiness, sweating, hunger, irritability, or confusion; severe lows can trigger seizures or heart rhythm changes. Children and older adults are more vulnerable to neuroglycopenic symptoms. During pregnancy, lower targets are common, but hypoglycemia can be harder to sense.
When eAG is high, it signals sustained hyperglycemia and protein glycation that stiffens arteries and injures small vessels in the retina, kidney, and peripheral nerves. Thirst, frequent urination, blurry vision, fatigue, and infections may appear. In teens, puberty's insulin resistance can push eAG higher. In pregnancy, elevated eAG raises risks for large‑for‑gestational‑age infants and hypertensive disorders.
When eAG misrepresents true glucose
Interpretation assumes normal red blood cell lifespan and a reliable A1c assay. Iron deficiency can artifactually raise, while hemolysis, recent blood loss/transfusion, pregnancy, advanced kidney or liver disease, and some hemoglobin variants can lower or otherwise bias the estimate. eAG does not capture glucose swings or frequency of lows.
Using eAG with sensor and fasting data
Estimated Average Glucose translates your hemoglobin A1c into the language of day‑to‑day blood sugar. It reflects your typical glucose exposure over the past 2–3 months (weighted toward the most recent weeks). This matters because chronic glucose levels shape how efficiently cells make energy, how insulin signals, and how blood vessels, kidneys, nerves, eyes, the brain, and the immune system age and perform. Low values usually reflect either genuinely lower average glucose or conditions that shorten red blood cell lifespan and falsely lower the estimate. True low averages often come with more episodes of low blood sugar, which can cause shakiness, fatigue, and confusion (neuroglycopenia). In pregnancy, targets are lower than usual, but very low averages can still signal hypoglycemia risk. Being in range suggests stable glucose exposure with adequate insulin action and beta‑cell reserve, low glycation stress, and a lower likelihood of microvascular injury. In otherwise healthy adults, optimal often sits in the lower‑to‑mid portion of the standard range so long as lows are uncommon. High values usually reflect sustained hyperglycemia from insulin resistance and/or reduced insulin secretion. This increases protein glycation and endothelial stress, raising risks for cardiovascular disease, kidney strain, neuropathy, retinopathy, infections, and cognitive decline. In pregnancy, higher values point to gestational dysglycemia and risks such as fetal overgrowth.
FAQs
Estimated Average Glucose (eAG) is the translation of HbA1c into a mean glucose value in mg/dL, reflecting average blood sugar over the previous 8–12 weeks.
eAG is calculated from HbA1c using a validated equation: eAG (mg/dL) = 28.7 × HbA1c − 46.7.
eAG summarizes long-term glucose exposure, relates to complication risk, and lets you compare lab results to CGM or meter readings in the same units.
Because eAG reflects about three months of history, many people reassess every 3 months, or every 6–12 months if stable and not making major changes.
Diet, physical activity, sleep, stress, illness, and glucose-lowering medications can all influence average glucose and therefore eAG.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Nathan, D. M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D., & Heine, R. J. (2008). Translating the A1C assay into estimated average glucose values. Diabetes Care, 31(8), 1473-1478. https://doi.org/10.2337/dc08-0545
- American Diabetes Association Professional Practice Committee. (2024). 6. Glycemic goals and hypoglycemia: Standards of care in diabetes-2024. Diabetes Care, 47(Suppl. 1), S111-S125. https://doi.org/10.2337/dc24-S006
- American Diabetes Association Professional Practice Committee. (2024). 2. Diagnosis and classification of diabetes: Standards of care in diabetes-2024. Diabetes Care, 47(Suppl. 1), S20-S42. https://doi.org/10.2337/dc24-S002
- Stratton, I. M., Adler, A. I., Neil, H. A., Matthews, D. R., Manley, S. E., Cull, C. A., Hadden, D., Turner, R. C., & Holman, R. R. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ, 321(7258), 405-412. https://doi.org/10.1136/bmj.321.7258.405
- Hantzidiamantis, P. J., Awosika, A. O., & Lappin, S. L. (2024). Physiology, glucose. In StatPearls. StatPearls Publishing. https://pubmed.ncbi.nlm.nih.gov/31424785/






































.avif)
